RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort

Leukemia, Published online: 20 October 2023; doi:10.1038/s41375-023-02027-3RAS-pathway mutations are common in patients with ruxolitinib refractory/intolerant myelofibrosis: molecular analysis of the PAC203 cohort

Source: Leukemia - October 20, 2023 Category: Hematology Authors: J. M. O ’Sullivan J. Taylor A. Gerds S. Buckley C. N. Harrison S. Oh A. F. List K. Howard H. Dreau A. Hamblin A. J. Mead Source Type: research